# EDGAR Filing Document

**Accession Number:** 0001651308
**File Stem:** 0000000000-25-005783
**Filing Date:** 2025-6
**Character Count:** 3743
**Document Hash:** 0036713929124eeda12b5c556def1b03
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-005783.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0000000000-25-005783

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250602

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BeOne Medicines Ltd.
- **CENTRAL INDEX KEY:** 0001651308
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981209416
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-37686

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O BEONE MEDICINES I GMBH
- **STREET 2:** AESCHENGRABEN 27, 21ST FLOOR
- **CITY:** BASEL
- **PROVINCE COUNTRY:** V8
- **ZIP:** 4051
- **BUSINESS PHONE:** 41-616851900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O BEONE MEDICINES I GMBH
- **STREET 2:** AESCHENGRABEN 27, 21ST FLOOR
- **CITY:** BASEL
- **PROVINCE COUNTRY:** V8
- **ZIP:** 4051

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BeiGene, Ltd.
- **DATE OF NAME CHANGE:** 20150819
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001651308-25-000031

## Text-Extract

```

                                                           June 2, 2025

Aaron Rosenberg
Chief Financial Officer
BeOne Medicines Ltd.
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay

       Re: BeOne Medicines Ltd.
           Form 10-K for the Fiscal Year Ended December 31, 2024
           File No. 001-3786
Dear Aaron Rosenberg:

       We have reviewed your filing and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-K for Fiscal Year Ended December 31, 2024
Notes to the Consolidated Financial Statements
3. Collaborative and Licensing Arrangements, page 151

1.     You disclose that other collaboration revenue consists primarily of
revenue under the
       Novartis broad markets agreement and, beginning in 2024, royalty revenue
under the
       Amgen collaboration agreement. Please revise your future filings to
clarify the
       products to which the Amgen royalty revenue relates. In this regard,
your disclosure
       on page 153 indicates that beginning in October 2019 you were
responsible for the
       commercialization of XGEVA, KYPROLIS and BLINCYTO in China for a period
of
       five to seven years, and that following the commercialization period you
have the
       right to retain one product and receive royalties on sales in China for
an additional
       five years on the products not retained. Clarify whether the
commercialization period
       has ended for any of these products and if not, to which products the
royalty revenue
       relates.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.
 June 2, 2025
Page 2

      Please contact Bonnie Baynes at 202-551-4924 or Angela Connell at
202-551-
3426 with any questions.

                                                       Sincerely,

                                                       Division of Corporation
Finance
                                                       Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._